Krystal Biotech KRYS announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Vyjuvek ...
or B-VEC) for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB). The intended DEB patient population includes those who have mutations in the COL7A1 gene starting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback